cbdMD, Inc. Achieves Compliance with NYSE American Standards
cbdMD, Inc. (NYSE American: YCBD), a significant leader in wellness and hemp-derived products, has reached a notable milestone by regaining full compliance with the NYSE American listing standards. This positive announcement signifies the removal of the noncompliance indicator from the list of issuers, effective now as trading reopens. This accomplishment not only reflects the strategic efforts put forth by the company but also represents a commitment to maintaining solid governance and operational oversight.
Importance of Compliance
The NYSE American’s confirmation of compliance came formally through a notification letter, indicating that cbdMD successfully addressed all noted deficiencies. These deficiencies were specifically connected to the NYSE American Company Guide’s sections, which outline the essential operational standards listed companies must adhere to. The swift resolution of these issues highlights the power of effective management and rigorous financial oversight within the organization.
CEO’s Commitment
Ronan Kennedy, the CEO of cbdMD, expressed enthusiasm regarding this achievement, emphasizing the importance of maintaining a listing on the NYSE American. He noted, “Preserving our NYSE American listing was a critical achievement and reflects the tremendous work completed this year.” His sentiments underline the strategic initiatives taken by the company in navigating toward sustainable growth.
Strategic Financial Measures
cbdMD's success in achieving compliance is largely attributed to its proactive strategies, including a successful Series A Preferred share conversion earlier this year, alongside a capital raise in September. These pivotal actions not only bolstered the company’s financial health but also reinforced the dedication of their investors and stakeholders toward the long-term vision of cbdMD.
Future Goals and Monitoring
As cbdMD moves forward, it will remain under the careful monitoring procedures of the NYSE American. The company is dedicated to upholding rigorous financial standards and corporate governance, ensuring that it maintains its compliance status long-term. This commitment is integral in building trust with investors and enhancing shareholder value in the competitive wellness industry.
About cbdMD, Inc.
cbdMD, Inc. stands out as one of the most recognized and trusted cannabidiol (CBD) brands in the market. Featuring a diverse array of products, the company adheres to Farm Act compliance for its offerings. The range of products includes various CBD formulations and specialty items such as those from its Paw CBD brand, designed specifically for pets, as well as its Herbal Oasis THC Seltzer and the ATRx brand focused on natural functional mushroom support. To explore more about these offerings, individuals are encouraged to visit the official cbdMD website and other associated brand websites, which showcase their commitment to high-quality hemp and wellness products.
Frequently Asked Questions
What is the significance of cbdMD regaining compliance?
Regaining compliance with NYSE American standards helps cbdMD maintain its market position and fosters investor confidence.
What were the key factors for cbdMD's compliance success?
Successful financial strategies, including share conversions and capital raises, played a crucial role in their regaining compliance.
How does cbdMD plan to maintain its compliance?
The company is committed to high financial discipline and governance while complying with ongoing monitoring procedures.
Who is the current CEO of cbdMD?
Ronan Kennedy is the Chief Executive Officer and Chief Financial Officer of cbdMD, Inc.
What products does cbdMD offer?
cbdMD offers a comprehensive line of CBD products, including pet formulations, wellness beverages, and functional mushroom support products.
